Table 4 Patients characteristics survival.

n

90

94

Male

60 (66.7%)

74 (78.7%)

Age [years]

64 (58;70)

25–83

68 (63; 75)

33–92

< 0.05

Body-Mass-Index [kg/m²]

30.45 (26.12; 34.26)

20.81–52.47

27.78 (25.48; 33.14)

18.94–70.31

Time from first symptom to hospital admission [days]

5 (0; 7)

0–50

4.5 (0; 8)

0–23

Time from first symptom to admission to our ICU [days]

10 (5; 14)

0–28

11 (5; 16)

0–35

Time from first symptom to ECMO therapy [days]

16 (13; 22)

4–25

15 (11; 23)

0–31

Direct transfer to our ICU from other hospital

55 (61.1%)

66 (70.2%)

External tracheostomy

6 (6.7%)

8 (8.5%)

External intubation

60 (66.7%)

73 (77.7%)

Invasive mechanical ventilation before admission to our ICU [days]

2 (0; 5)

0–20

3 (0; 7)

0–16

Non-invasive mechanical ventilation before admission to our ICU [days]

2 (1; 3)

1–18

2 (1; 4)

1–22

Charlson ComorbidityIndex

3 (2; 5)

0–11

3 (2; 6)

0–12

Arterial Hypertension

66 (73.3%)

65 (69.1%)

Cardiovascular disease

21 (23.3%)

24 (25.5%)

Neurovascular symptoms

9 (10%)

9 (9.6%)

Coronary artery disease

15 (16.7%)

16 (17.0%)

Thromboembolic events in medical history

4 (4.4%)

7 (7.4%)

Chronic arrhythmias

14 (15.6%)

23 (24.5%)

COPD

8 (8.9%)

5 (5.3%)

Other pulmonary disease

3 (3.3%)

8 (8.5%)

Nicotine abuse

8 (8.9%)

4 (4.3%)

Diabetes mellitus

42 (46.7%)

37 (39.4%)

Previous organ or bone marrow transplantation

4 (4.4%)

5 (5.3%)

Chronic renal failure

12 (13.3%)

16 (17.0%)

Chronic need of renal replacement therapy

1 (1.1%)

7 (7.4%)

Admission with trauma

6 (6.7%)

2 (2.1%)

ACE inhibitors

26 (28.9%)

17 (18.3%)

AT2 receptor blocker

23 (25.6%)

29 (31.2%)

Beta blocker

36 (40.0%)

38 (40.9%)

Antithrombotic drug

24 (26.7%)

25 (26.9%)

DOAC

13 (14.4%)

17 (18.3%)

Corticosteroids

11 (12.2%)

10 (10.8%)

Immunosuppressive Drugs

4 (4.4%)

6 (6.5%)

Nosocomial infection

8 (8.9%)

11 (11.7%)